U.S. Basal Cell Carcinoma Treatment Market Size & Outlook
U.S. basal cell carcinoma treatment market, 2018-2030 (US$M)
Related Markets
U.S. basal cell carcinoma treatment market highlights
- The U.S. basal cell carcinoma treatment market generated a revenue of USD 1,544.1 million in 2023 and is expected to reach USD 3,071.8 million by 2030.
- The U.S. market is expected to grow at a CAGR of 10.3% from 2024 to 2030.
- In terms of segment, surgery was the largest revenue generating type in 2023.
- Intravenous Medications is the most lucrative type segment registering the fastest growth during the forecast period.
Basal cell carcinoma treatment market data book summary
| Market revenue in 2023 | USD 1,544.1 million |
| Market revenue in 2030 | USD 3,071.8 million |
| Growth rate | 10.3% (CAGR from 2023 to 2030) |
| Largest segment | Surgery |
| Fastest growing segment | Intravenous Medications |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Radiotherapy (RT), Intravenous Medications, Chemical peeling treatment, Surgery, Topical chemotherapy, Oral Medications |
| Key market players worldwide | Bausch Health Companies Inc, Almirall SA, Genentech, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Dr Reddy's Laboratories Ltd ADR, Taro Pharmaceuticals, Accord Healthcare |
Other key industry trends
- In terms of revenue, U.S. accounted for 52.1% of the global basal cell carcinoma treatment market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. basal cell carcinoma treatment market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 364.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Basal Cell Carcinoma Treatment Market Scope
Basal Cell Carcinoma Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. basal cell carcinoma treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to basal cell carcinoma treatment market will help companies and investors design strategic landscapes.
Surgery was the largest segment with a revenue share of 36.26% in 2023. Horizon Databook has segmented the U.S. basal cell carcinoma treatment market based on radiotherapy (rt), intravenous medications, chemical peeling treatment, surgery, topical chemotherapy, oral medications covering the revenue growth of each sub-segment from 2018 to 2030.
In the U.S., skin cancer is the most prevalent form of cancer, with approximately one in five individuals expected to develop it during their lifetime. According to the American Cancer Society, approximately 5.4 million squamous & basal cell skin cancers are diagnosed each year in the U.S.
Increasing cases of basal cell carcinoma in country is expected to support market growth. According to International Agency for Research on Cancer, in 2022, the U.S. reported 475,093 cases of NMSC.
Reasons to subscribe to U.S. basal cell carcinoma treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. basal cell carcinoma treatment market databook
-
Our clientele includes a mix of basal cell carcinoma treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. basal cell carcinoma treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. basal cell carcinoma treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. basal cell carcinoma treatment market size, by type, 2018-2030 (US$M)
U.S. Basal Cell Carcinoma Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
